TRCT
AMLX icon

Tower Research Capital (TRC)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Tower Research Capital (TRC)’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
7,934
+21
+0.3% +$325 ﹤0.01% 1938
2026
Q1 		$110K Sell
7,913
-182
-2% -$2.56K ﹤0.01% 2101
2025
Q4 		$97.8K Buy
8,095
+1,505
+23% +$20.4K ﹤0.01% 1965
2025
Q3 		$89.6K Sell
6,590
-877
-12% -$8.26K ﹤0.01% 2088
2025
Q2 		$47.9K Buy
7,467
+664
+10% +$3.23K ﹤0.01% 3015
2025
Q1 		$24.1K Sell
6,803
-39,184
-85% -$139K ﹤0.01% 2795
2024
Q4 		$174K Buy
45,987
+36,347
+377% +$171K ﹤0.01% 1812
2024
Q3 		$31.2K Sell
9,640
-22,296
-70% -$50.1K ﹤0.01% 2976
2024
Q2 		$60.7K Buy
31,936
+21,640
+210% +$41.9K ﹤0.01% 2947
2024
Q1 		$29.2K Sell
10,296
-2,018
-16% -$26.4K ﹤0.01% 2671
2023
Q4 		$181K Buy
12,314
+8,343
+210% +$128K ﹤0.01% 2184
2023
Q3 		$72.7K Sell
3,971
-295
-7% -$6.24K ﹤0.01% 2237
2023
Q2 		$92K Buy
4,266
+2,454
+135% +$66.3K ﹤0.01% 2083
2023
Q1 		$54K Sell
1,812
-86
-5% -$2.99K ﹤0.01% 2409
2022
Q4 		$70K Sell
1,898
-1,160
-38% -$41.2K ﹤0.01% 2100
2022
Q3 		$86K Sell
3,058
-282
-8% -$7.04K ﹤0.01% 2688
2022
Q2 		$64K Buy
3,340
+2,629
+370% +$31.2K ﹤0.01% 2652
2022
Q1 		$10K Buy
+711
New +$16.1K ﹤0.01% 4271

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tower Research Capital (TRC)'s AMLX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Amylyx Pharmaceuticals (AMLX) stake by 0.27% in Q2 2026, buying an estimated $325 and bringing the position to 7,934 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

Tower Research Capital (TRC) first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $181K in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Tower Research Capital (TRC) held 7,934 shares of Amylyx Pharmaceuticals worth $142K as of Q2 2026.
  • Tower Research Capital (TRC) bought 21 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $325.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1938 holding.
  • Tower Research Capital (TRC) first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Amylyx Pharmaceuticals position peaked at $181K in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.